Quarterly ResultAug 6, 2026, 07:01 AM
Sionna Therapeutics' SION-719 & SION-451 Trials On Track for Summer Data
AI Summary
Sionna Therapeutics reported its second-quarter 2026 financial results and provided a business update, highlighting significant progress in its clinical pipeline. The company's PreciSION CF Phase 2a trial for SION-719 and the Phase 1 dual combination trial for SION-451 are both on track to deliver topline data in summer 2026. Financially, Sionna maintained a strong cash position with $268.3 million in cash and equivalents, projected to fund operations into 2028, despite an increased net loss of $29.9 million for the quarter due to higher R&D and G&A expenses.
Key Highlights
- PreciSION CF Phase 2a trial for SION-719 on track for topline data summer 2026.
- Phase 1 dual combination trial for SION-451 on track for topline data summer 2026.
- Cash and cash equivalents totaled $268.3 million as of June 30, 2026.
- Cash position expected to fund operations into 2028.
- Q2 2026 R&D expenses increased to $21.9 million from $15.4 million YoY.
- Q2 2026 G&A expenses increased to $10.6 million from $6.5 million YoY.
- Q2 2026 net loss was $29.9 million, compared to $18.1 million YoY.
Price Impact
More from SION